| Literature DB >> 32316698 |
Eswaran Ramachandran1,2, Valentina Gandin3, Roberta Bertani1, Paolo Sgarbossa1, Karuppannan Natarajan4, Nattamai S P Bhuvanesh5, Alfonso Venzo6, Alfonso Zoleo6, Mirto Mozzon1, Alessandro Dolmella3, Alberto Albinati7, Carlo Castellano7, Nuno Reis Conceição8, M Fátima C Guedes da Silva8, Cristina Marzano3.
Abstract
Three new 6-methyl-2-oxo-1,2-dihydroquinoline-3-carbaldehyde-thiosemicarbazones-N-4-substituted pro-liEntities:
Keywords: EPR and electrochemical measurements; TEM images; X ray crystal structure; copper thiosemicarbazones complexes; cytotoxicity in 3D spheroids
Year: 2020 PMID: 32316698 PMCID: PMC7221752 DOI: 10.3390/molecules25081868
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Chart 1Thiosemicarbazones with known medicinal effects.
Scheme 1The synthetic route of the ligands and Cu(II) complexes.
Figure 1The Z(cis) and E(trans) rotamers of H2L1 (Y = NH2) and H2L2 (Y = NHCH3) (or H2L3, Y = NHCH2CH3) [97].
Figure 2CW-EPR of the samples 1 (left) and 3 (right) in ethanol at 80 K. Black continuous line: experimental spectrum; dotted line: simulated spectrum of 1; grey continuous line: the low-field region expanded to show all the features. The vertical lines mark the position of each quartet due to a different species.
Parameters obtained from the simulations for the CW-EPR spectra of samples 1 and 3 in ethanol at 80 K. Hyperfine constants A, A and A are in cm−1.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
| 2.388 | 137 × 10−4 | 2.07 | 2.08 | 3.3 × 10−4 | 3.3 × 10−4 |
|
| 2.260 | 173 × 10−4 | 2.07 | 2.10 | 5.0 × 10−4 | 5.0 × 10−4 |
|
| 2.385 | 147 × 10−4 | 2.01 | 2.08 | 4.0 × 10−4 | 4.0 × 10−4 |
|
| 2.350 | 182 × 10−4 | 2.07 | 2.10 | 5.0 × 10−4 | 5.0 × 10−4 |
Figure 3Cyclic voltammogram for H2L2 (C = 2.00 × 10−3 M) in [NBu4][BF4] 0.2 M in DMSO at a platinum disc working electrode (d = 0.5 mm) and at a scan rate of 0.2 V.s−1. The arrow indicates the cathodic initial scan direction.
Cyclic voltammetry data 1 for the thiosemicarbazone pro-ligands and their Cu(II) complexes.
| Compound | Cathodic Peak Potential | Anodic Peak Potential 3 | ||
|---|---|---|---|---|
| Lred | Ired 2 | A | Iox | |
| H2L1 | −1.56 | |||
|
| −1.59 | −0.26 | −0.05 | 0.36 |
|
| −1.56 | −0.32 | −0.05 | 0.27 |
|
| −1.56 | −0.31 | −0.07 | 0.24 |
1 Potential values (in Volt ± 0.02) relative to SCE, measured by CV at a Pt electrode in DMSO/0.2 M [NBu4][BF4] at 0.2 V·s−1. 2 Broad wave which split into two at low scan rates (see text). 3 Redox processes detected only upon reversing the potential scan direction at a low cathodic potential limit, or after the formation of wave Ired at sufficiently low scan rates.
Figure 4Cyclic voltammogram for complex 2 (C = 2.98 x 10−3 M) in [NBu4][BF4] 0.2 M in DMSO at a platinum disc working electrode (d = 0.5 mm), at 0.2 V·s−1 (top, including offset CV) and at 0.05 V·s−1 (bottom). The arrows indicate the cathodic initial scan direction.
Figure 5Ortep view of the cation in complex 2. (Ellipsoids drawn at 50% probability; the numbering scheme used is just for comparison purposes in the following tables).
Selected Bond Lengths (Å) and Angles (deg) for 2 and 1.
| 2 | 1a * | 1b * | |
|---|---|---|---|
| Cu1–O1 | 1.948(3) | 1.973(3) | 1.946(3) |
| Cu1–S1 | 2.266(2) | 2.289(2) | 2.278(1) |
| Cu1–N2 | 1.977(3) | 1.975(3) | 1.969(3) |
| Cu1–Ow1 | 1.928(3) | 1.961(2) | 1.943(3) |
| Cu1–Ow2 | 2.226(4) | 2.254(2) | |
| Cu1–ON1 | 2.695(4) | ||
| Cu1–ON2 | 2.525(4) | ||
| N2–Cu1–Ow2 | 96.6(1) | 100.7(1) | 88.5(3) |
| Ow1–Cu1–Ow2 | 90.9(2) | 97.0(1)) | 82.2(2) |
| Ow1–Cu1–ON1 | 113.2(2) | ||
| N2–Cu1–Ow1 | 172.4(1) | 169.2(1) | 170.6(1) |
| ON1–Cu1–ON2 | 158.1(2) |
* 1a and 1b refer to the two independent molecules in the unit cell of compound 1.
Figure 6Ortep view of 1a, one of the two independent cations in the unit cell of 1 (Ellipsoids drawn at 50% probability; the numbering scheme used is just for comparison purposes in the following tables).
Figure 7Ortep view of 1b, of the second cation in 1 (Ellipsoids drawn at 50% probability).
Figure 8Ortep view of 3a (Ellipsoids drawn at 50% probability; the numbering scheme used is just for comparison purposes in the following tables).
Figure 9Ortep view of 3b (Ellipsoids drawn at 50% probability).
Selected bond lengths (Å) and angles (deg) for 3.
| 3a(Cu1) * | 3b(Cu2) * | |
|---|---|---|
| Cu–O1 | 1.930(3) | 1.929(3) |
| Cu–S1 | 2.263(1) | 2.258(1) |
| Cu–N2 | 1.986(3) | 1.977(3) |
| Cu–Om1 | 1.989(3) | |
| Cu–Ow1 | 1.931(3) | |
| Cu–ON1 | 2.318(3) | 2.388(3) |
| N2–Cu–O1 | 90.8(1) | 91.3(1) |
| N2–Cu–S1 | 87.0(1) | 87.4(1) |
| N2–Cu–ON1 | 122.3(1) | 86.4(1) |
| ON1–Cu–Om1 | 80.1(1) | |
| ON1–Cu–Ow1 | 91.7(1) | |
| S1–Cu–ON1 | 90.86(8) | 99.93(8) |
| N2–Cu–Om1 | 157.6(1) | |
| N2–Cu–Ow1 | 178.0(1) | |
| S1–Cu–O1 | 177.16(9) | 168.12(9) |
* 3a and 3b refer to the two independent molecules in the unit cell of compound 3, shown in Figure 8 and Figure 9, respectively.
Cytotoxicity studies.
| IC50(µM) ± S.D. | |||||
|---|---|---|---|---|---|
| Compounds | HCT-15 | A549 | BxPC3 | PSN-1 | A375 |
|
| 8.4 ± 1.7 | 6.8 ± 1.3 | 7.8 ± 0.5 | 9.2 ± 1.6 | 0.6 ± 0.2 |
|
| >25 | >50 | 16.8 ± 2.6 | 18.3 ± 2.8 | 17.5 ± 3.2 |
|
| 2.6 ± 1.2 | 5.6 ± 0.5 | 0.1 ± 0.08 | 4.6 ± 2.0 | 0.027 ± 0.005 |
|
| >25 | >50 | >25 | >100 | >25 |
|
| 1.7 ± 1.5 | 3.2 ± 0.6 | 0.3 ± 0.2 | 5.3 ± 0.3 | 0.031 ± 0.001 |
|
| 23.4 ± 1.0 | >25 | >25 | >100 | >100 |
|
| 15.5 ± 3.8 | 6.9 ± 2.1 | 13.9 ± 5.9 | 13.5 ± 4.1 | 1.3 ± 0.6 |
The IC50 values were calculated by the four parameter logistic model (p < 0.05). Cells (3–8·103·mL−1) were treated for 72 h with increasing concentrations of tested compounds dissolved in DMSO (Cytotoxicity was assessed by MTT test). S.D. = standard deviation.
Cross-resistance profiles.
| IC50(µM) ± S.D. | ||||||
|---|---|---|---|---|---|---|
| Compounds | 2008 | C13* | R.F. | LoVo | LoVo-OXP | R.F. |
|
| 9.7 ± 3.3 | 6.7 ± 1.2 | 0.7 | 0.7 ± 0.07 | 1.2 ± 0.6 | 1.8 |
|
| 11.2 ± 2.0 | 8.5 ± 3.5 | 0.8 | 1.9 ± 0.6 | 2.0 ± 0.04 | 1.1 |
|
| 2.8 ± 0.9 | 0.9 ± 0.7 | 0.3 | 0.7 ± 0.5 | 1.1 ± 0.1 | 1.6 |
|
| 2.1 ± 0.6 | 26.9 ± 4.3 | 12.8 | |||
|
| 3.1 ± 0.3 | 53.4 ± 0.8 | 17.2 | |||
The IC50 values were calculated by the four parameter logistic model (p < 0.05). Cells (3–8·103·mL−1) were treated for 72 h with increasing concentrations of tested compounds dissolved in DMSO. Cytotoxicity was assessed by MTT test. R.F. = IC50 (resistant subline)/IC50 (wild-type cells). S.D. = standard deviation.
Cytotoxicity against non-cancerous cells.
| Compounds | HEK293 | SI |
|---|---|---|
|
| 3.9 ± 3.1 | 6.5 |
|
| 1.3 ± 0.8 | 41.9 |
|
| 1.1 ± 0.2 | 47.8 |
|
| 21.6 ± 3.5 | 16.6 |
The IC50 values were calculated by a four parameter logistic model (p < 0.05). Cells (5·103·mL−1) were treated for 72 h with increasing concentrations of tested compounds dissolved in DMSO. Cytotoxicity was assessed by MTT test. SI A375 = IC50 HEK293 non-cancer cells/IC50 A375 cancer cells. S.D. = standard deviation.
Cytotoxicity towards human cancer cell spheroids.
| IC50(µM) ± S.D. | ||
|---|---|---|
| Compounds | HCT-15 | A375 |
|
| 14.9 ± 2.3 | 18.6 ± 3.9 |
|
| 6.50 ± 0.80 | 7.6 ± 1.7 |
|
| 16.0 ± 2.8 | 11.3 ± 2.5 |
|
| 54.75 ± 1.26 | 32.8 ± 6.1 |
Spheroids (3∙103 cells/well) were treated for 72 h with increasing concentrations of tested compounds. The growth inhibitory effect was evaluated by means of the APH assay. IC50 values were calculated from the dose-survival curves by the four-parameter logistic model (p < 0.05). S.D. = standard deviation.
Figure 10Cellular uptake in cancer cells. A375 cancer cells were incubated with 2 µM of copper complexes for 12 or 24 h, and the cellular copper content was detected by a GF-AAS analysis. Error bars indicate the standard deviation. ** p < 0.01.
Figure 11Left: DNA fragmentation. A375 cells were treated for 24 h with IC50 values of tested compounds and were then processed for nucleosome formation. The error bars indicate the S.D. Right: ROS production. A375 cells were pre-incubated in PBS/10 mM glucose medium for 20 min at 37 °C in the presence of 10 µM CM-H2DCFDA and were then treated with IC50 of compounds 1–3. The error bars indicate the S.D. ** p < 0.01; * p < 0.05.
Figure 12TEM analysis of A375 cells: (a,b): control cells; (c,d): A375 cells treated for 24 h with IC50 concentrations of 2; (e,f): A375 cells treated for 24 h with IC50 concentrations of 3.